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Abstract (194/200 words) 
Background: RAS (NRAS+KRAS) mutation testing is required in addition to simple KRAS 
testing prior to initiating anti-epidermal-growth-factor-receptor (EGFR) antibodies (MAb) as 
in metastatic colorectal cancer (mCRC). 
Aims: To assess prescription and implementation rates of RAS/KRAS mutation testing. To 
describe the RAS/KRAS mutation test procedure and its impact on therapeutic strategy. 
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Patients and Methods: Observational retrospective study conducted from June to September 
2014 in all consecutive patients with newly diagnosed mCRC. 
Results: Data from 375 patients (male: 57.8%; mean age, 65.7±11.7 years) were analysed. 
RAS/KRAS mutation testing was prescribed in 90.1% of patients (338/375). The test was 
prescribed within 1 month around mCRC diagnosis and prior to first-line therapy in 73.1% 
(242/331) and 85.4% (280/328) of patients, respectively. Time from test request to receipt of 
results was 24.6±17.2 days. 59.7% of patients (190/318) had a mutation, mainly KRAS 
(47.9%; 152/317). Anti-EGFR MAb was prescribed in 90.9% of RAS-wild-type cases (60/66), 
consistent with the goal of genotyping-testing in this population. 
Conclusion: In 2014, RAS genotyping-testing in addition to KRAS testing was routinely 
prescribed and performed in mCRC patients in France. Time to receive results remains long 
and must be reduced so as to match clinical practice. 
 
Key words: RAS; KRAS mutations; genotyping; colorectal cancer (4/4 key words) 
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Introduction 
 
Colorectal cancer (CRC) is the second most common cause of cancer death in Europe, with 
446,800 new CRC diagnoses and 214,700 disease-related deaths in 2012 [1]. Approximately 
20% of the patients have metastatic disease at initial diagnosis, and an additional 30% to 40% 
develop metastases during the course of the disease [2]. Twenty years ago, patients with 
metastatic colorectal cancer (mCRC) had a 5-year survival rate of only 11% [2]. Progress has 
been made through improvements in treatment, including targeted therapies. Anti-epidermal 
growth factor receptor monoclonal antibodies (anti-EGFR MAb) such as cetuximab and 
panitumumab have emerged as effective in a subset of mCRC patients and were initially 
approved in refractory mCRC, but then reported to be ineffective in tumours with mutations 
in codons 12 and 13 of exon 2 of the KRAS gene [3, 4]. In addition to the KRAS exon 2 
mutation, in 2013 it was shown that mutations in KRAS exons 3 and 4, and in NRAS exons 2 
to 4 had similar negative impact on anti-EGFR MAb efficacy [5], and anti-EGFR MAbs were 
therefore restricted to mCRC patients without so-called “RAS mutations” (KRAS or NRAS 
mutations), improving target population definition. 
In 2011, we conducted the French national Flash-KRAS study, showing that KRAS testing 
(exon 2 exclusively) was well-established in the management of mCRC patients in clinical 
practice in France, despite some regional discrepancies [6]. In 2014, we conducted the present 
Flash-RAS observational study to assess whether the genotyping tests were performed in 
accordance with the intervening changes in approved indications for anti-EGFR MAbs. The 
primary objective was to evaluate the prescription and implementation rates of RAS mutation 
testing in newly diagnosed mCRC patients (approved indication). Secondary objectives 
comprised analysis of reasons for non-prescription of testing, timing of the RAS testing 
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process from prescription to results, techniques used to determine RAS status, and impact of 
RAS status on treatment strategy. 
 
Patients & Methods 
 
Patient selection 
 
This national multicentre non-interventional retrospective study was conducted with 
oncologists, gastroenterologists, and radiotherapists treating patients with mCRC in mainland 
France. Participating physicians were to screen consecutive patients seen in daily practice 
satisfying the following criteria: age ≥18 years, with mCRC confirmed histologically after 
March 2014 (date at which the NRAS tests became available in France), seen in consultation 
between June 15th, 2014 and September 30th, 2014, and initiating or having initiated first-line 
therapy for mCRC during that period. The study complied with the principles of the 
Declaration of Helsinki and the international directives (ICH3) for non-interventional studies. 
All participants gave oral consent prior to inclusion. 
 
Data collection 
 
Data were collected from patients’ medical files and recorded in a questionnaire collecting 
patient and tumour characteristics, first-line chemotherapy, details of the RAS/KRAS mutation 
test process (i.e., NRAS+KRAS or KRAS exons 2, 3 and 4, sometimes in association with 
BRAF) from test request to reception of results, reason(s) for request or non-request for 
mutation testing, and impact of results on therapeutic management. When available, an 
anonymized copy of the genotyping test report was added to the questionnaire. 
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Statistical Analysis 
 
Patients’ demographic and disease characteristics and treatments were reported as standard 
statistics: mean and standard deviation (SD), median, range, interquartile range for 
quantitative parameters, and number and percentage for qualitative parameters (excluding 
missing data). Statistical analysis used SAS® software, version 9.2, (SAS Institute Inc., Cary, 
NC, USA). The number and percentage of requests for RAS mutation testing were reported 
with their 95% confidence interval (95%CI). Analysable patients were all patients enrolled in 
the study and respecting selection criteria. 
 
Results 
 
Centres, patients and disease characteristics 
 
2,700 oncologists, gastroenterologists, and radiotherapists, representative of the nationwide 
population of physicians treating CRC, were invited to participate in the study: 298 accepted, 
and 104 finally enrolled a total of 406 patients (median: 3 patients per physician). Mean age 
of physicians was 44.5 ± 7.1 years; the majority were male (61.2%), and most were practicing 
in private clinics/hospitals (41.2%), or general hospitals (30.6%). 
Data for 375 of the 406 enrolled patients were analysed (Table 1). The most commonly used 
first-line chemotherapies were FOLFOX and/or XELOX (51.1%; 186/364) and FOLFIRI 
and/or IRINOTECAN (32.1%; 117/364). More than half of the patients (53.2%; 198/372) 
received targeted therapy. Desired location of Table 1 
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RAS/KRAS mutation test requests 
 
RAS/KRAS mutation testing was requested for 90.1% of patients (338/375) and a report of the 
results was available for 84.8% of patients (318/375) (Figure 1). Reasons for non-request 
were provided for 28 patients (9 missing data). The main reason for non-request was that no 
anti-EGFR MAb therapy was planned by the physician (57.1%; 16/28); other reasons 
included the patient’s age or general condition (10.7%; 3/28), scheduled metastasis resection 
surgery (10.7%; 3/28), excessive delay in obtaining test results (5.4%; 2/28), multidisciplinary 
team decision (7.1%; 2/28), and “other” (7.1%; 2/28). Desired location of Figure 1 
RAS/KRAS mutation testing was mainly requested by oncologists (50.4%; 169/335) and 
gastroenterologists (24.2%; 81/335). In most cases (86.4%; 286/331), physicians requested 
testing of both NRAS and KRAS (BRAF testing being sometimes requested in association with 
NRAS/KRAS). Simple KRAS mutation testing was requested for 9.2% of patients for whom a 
test was requested (31/338) (Table 2). The most frequently used technique of enrichment of 
mutated RAS gene alleles was pyrosequencing/sequencing/snapshot (59.8%; 202/338). 
Most patients (73.1%; 242/331) had a RAS/KRAS test request within 1 month around the 
diagnosis of metastatic disease. For 22.1% of patients (73/331), the test was requested more 
than 1 month after this diagnosis. It was requested before initiation of first-line therapy for 
85.4% of patients for whom a test was requested and data were available (280/328) (Table 2). 
Desired location of Table 2 
The oncogenetics platform was located outside the mCRC treatment centre for 80.7% of 
patients for whom a test was requested and data were available (268/332). The mean time 
between request for RAS/KRAS mutation testing and receipt of the results report was 24.6 ± 
17.2 days (median: 20 days). The duration of the overall process is detailed in Table 3. The 
median time for biomarker genotyping varied slightly according to analytic technique: 13 
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days for pyrosequencing and allelic discrimination, 10 days for high resolution melting, and 
12 days for other techniques. No patient-, tumour- or practitioner-related factors were 
significantly associated with time to obtain results. Desired location of Table 3 
 
Mutation test results 
 
59.7% of patients with available RAS (± BRAF) mutation results (190/318) had 1 mutation. 
KRAS mutations were identified in 47.9% of patients (152/317), NRAS mutations in 8.7% 
(20/231) and BRAF mutations in 10.0% (25/250). For 59.6% of patients (180/302), all 6 exons 
(KRAS exons 2, 3, 4 plus NRAS exons 2, 3, 4) were analysed. There were 44 patients with full 
RAS genotyping request for whom only KRAS exon 2 was in fact tested; in 41 of these cases, 
exon 2 was mutated, and this finding likely stopped the genotyping sequence. 
 
Impact of RAS mutations on therapeutic management 
 
According to the physicians, RAS mutation status had an impact on the therapeutic 
management of 94 of the 179 patients (52.5%) with 1 RAS mutation, and of 71 of the 120 
(59.2%) with wild-type RAS. Treatment changes, known for 76 of the 94 RAS-mutated 
patients, were, in decreasing order: anti-VEGF MAb initiation (bevacizumab: 39.5%; 30/76), 
no anti-EGFR MAb prescription despite being initially considered (22.4%; 17/76), and 
chemotherapy regimen change (17.1%; 13/76). Changes, known for 66 of the 71 wild-type 
RAS patients, were mainly anti-EGFR MAb (cetuximab, panitumumab) initiation (90.9%; 
60/66 patients) (Figure 2). An anti-EGFR MAb (cetuximab, panitumumab) was prescribed for 
10 of the 179 patients (5.6%) with a RAS mutation, despite the change in marketing 
authorizations. Desired location of Figure 2 
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Discussion 
 
This study was the first to describe the prevalence and procedure of RAS (KRAS+NRAS) 
mutation testing in routine practice at national level in France, since the approved indication 
for anti-EGFR MAbs in patients without activating RAS mutations.  
The study showed that RAS mutation testing was routinely performed as part of mCRC patient 
management in 2014 in France. Compared to 2011, the rate of genotyping testing requests 
increased from 81.1% in the 2011 Flash-KRAS study [6] to 90.1% in the present study, 
indicating clinical integration of anti-EGFR MAbs guidelines. For 9.2% of patients, mutation 
testing was requested for KRAS only, possibly because the study was conducted shortly after 
these recommendations were added to the cetuximab and panitumumab summaries of product 
characteristics [7, 8]. 
In 2014, as previously observed in the 2011 Flash-KRAS study [6], the test was prescribed 
early during mCRC patient management: within 1 month around the diagnosis of metastases 
in 73.1% of patients, and before initiation of first-line therapy in 85.4%. However, for 22.1% 
of the patients, the test was requested more than 1 month after diagnosis and, for 14.6%, after 
initiation of first-line therapy, which is not compatible with an informed choice of first-line 
treatment according to the patient’s RAS status.  
A mutation was identified in 59.7% of the patients, and mainly consisted in KRAS mutation. 
In more than half of the patients, all 6 exons were analysed (KRAS exons 2, 3, and 4 plus 
NRAS exons 2, 3, and 4). Genotyping was in some cases conducted sequentially, and in 44 
patients only KRAS exon 2 was analysed despite a request for full RAS genotyping, almost 
always because of early discovery of a KRAS exon 2 mutation. 
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Regarding time to obtain results, the mean time for the whole test procedure (from test request 
to the results feedback) was 24.6 ± 17.2 days (median: 20 days) in 2014, similar to that 
reported in the 2011 Flash-KRAS study (23.6 ± 28.2 days; median: 19 days). The narrower 
standard deviation, however, indicates a trend for more uniform feedback times in 2014, 
suggesting greater uniformity and coordination of mCRC patient management in the 
deployment of these new tests. This time interval was slightly shorter than reported in a 
previous French retrospective study [9] but remains long and hardly acceptable in clinical 
practice. The interval exceeded the maximum 10 working days recommended by European 
EQA schemes in 2013 [10], the 7-to-10 working days recommended by the French National 
Cancer Institute (INCa) in 2010 [11], and the median 9 days (range: 4-21 days) specified in 
the summary of the activity of the French hospital molecular genetics platforms in 2012 [12]. 
In a large study (2,510 tumour samples) performed in Germany from 2014 to 2016, 72% of 
RAS results were reported within 6 working days (lab turnaround time) [13]. In Canada, 
median turnaround time for EGFR results in lung cancer was 18 days (range: 15–26 days) in 
one study [14], and 21 days in another in which EGFR and ALK mutation tests were 
performed after the first oncology consultation [15]. In the present study, time from dispatch 
to the technical platform to reception of the report was longer in 2014 (19.5 ± 15.8 days; 
median: 15 days) than 2011 (mean 14.0 ± 11.0 days; median: 11 days), probably due to the 
greater number of exons tested (1 in 2011 versus 6 in 2014). 
The combination of pyrosequencing/sequencing/snapshot was the most frequent technique 
used for analysis of mutations, whatever the allele studied (KRAS, NRAS, or BRAF). This 
technique tended to replace sequencing by Sanger’s method, previously considered as the 
“gold standard’. According to the literature, between 7% and 20% of CRC cases characterised 
as wild-type by Sanger sequencing or real-time PCR were found to harbour KRAS codon 12 
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or 13 mutations on pyrosequencing, locked nucleic acid PCR or mutant-enriched PCR 
techniques [16-19]. 
With regard to the impact on therapeutic management, the results of RAS/KRAS mutation 
testing showed that, when absence of mutation was confirmed, a majority of patients (90.9%: 
60/66) were prescribed an anti-EGFR MAb, consistent with the goal of genotyping testing in 
this population. For a limited number of patients with a RAS mutation (5.6%: 10/179), an anti-
EGFR MAb (cetuximab, panitumumab) was prescribed, despite the restriction laid down in 
the market approval, which may suggest that there is still room for improvement in 
therapeutic practices. 
This study has some limitations owing to its observational nature, and possible selection bias 
for the physicians and patients participating. Only 104 of the 2,700 physicians contacted 
included at least 1 patient. Difficulties of recruitment led to a small number of included 
patients, which may limit extrapolation to a wider patient population. However, patient 
characteristics and distributions by centres and regions were representative of the population 
of mCRC patients, although 4 of the 22 French administrative Regions were overrepresented 
and 3 were not represented [20]. Missing data, especially concerning time between RAS/KRAS 
mutation test request and reception of the genotyping report, constituted another limitation. 
Liquid biopsy, analysing circulating tumour DNA (ctDNA), has emerged as new non-invasive 
procedure for detecting gene mutations in cancer patients. In a recent study, this method 
detected ctDNA in 100% of patients and exhibited high specificity (98%) and sensitivity 
(92%) for 7 KRAS point mutations [21]. While liquid biopsy is not yet well established in 
routine clinical practice, it could advantageously replace tumour section analysis for detection 
of RAS mutations, reducing procedure time. Liquid biopsy could bypass the time-consuming 
and therefore limiting steps of unarchiving, selecting and dispatching samples to the 
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oncogenetics platform. This method may, therefore, expand the scope of personalized 
medicine for cancer patients. 
 
In conclusion, this study showed that, in 2014, RAS mutation genotyping testing was a routine 
part of mCRC patient management in France. Compared to 2011, the rate of genotyping 
testing requests increased markedly. Overall, mCRC patient management was consistent with 
health authority guidelines, according to RAS status. However, the interval between test 
request and results feedback was longer than expected, and is not acceptable in clinical 
practice; this delay must be reduced. Standardization of assessment methods at European level 
could be a way to shorten this delay. 
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Figure 1: Study flowchart 
aA given patient might show several major protocol deviations: diagnosis of mCRC before 
2014 (N=11); refusal of data collection (N=10); no informed consent (N=4); >1 prior line of 
mCRC therapy (N=10); and/or participation in a concomitant interventional study (N=12). 
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Figure 2: Impact of RAS mutations on therapeutic management 
a318 of the 338 patients with at least 1 RAS/KRAS mutation test request (94.1%) had results 
available for RAS mutations. 
RAS: KRAS+NRAS or KRAS+NRAS+BRAF 
EGFR: epidermal growth-factor receptor; MAb: monoclonal antibody; VEGF: vascular 
endothelial growth factor 
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Table 1: Patient and tumour characteristics 
 Total  
(N=375) 
Gender, n (%) N=374 
Male 216 (57.8%) 
Age in years N=371 
Mean ± SD 65.7 ± 11.7 
Median 67 
Q1-Q3 58-74 
Location of primary tumour, n (%) N=370 
Colon 282 (76.2%) 
Rectum 86 (23.2%) 
Colon + Rectum 2 (0.5%) 
TNM Stage at the time of the CRC diagnosis, n (%) N=367 
I-II 38 (10.4%) 
III 59 (16.1%) 
IV 270 (73.6%) 
ECOG Performance status at study entry, n (%) N=350 
0 140 (40.0%) 
1 158 (45.1%) 
≥2 52 (14.9%) 
Time (months) between diagnostic of mCRC and initiation of the 
first line chemotherapy 
N=368 
Mean ± SD 1.11 ± 0.70 
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Median 1 
Q1-Q3 0.6-1.5 
First-line metastatic chemotherapy, n (%) N=364 
FOLFOX and/or XELOX 186 (51.1%) 
FOLFIRI and/or IRINOTECAN 117 (32.1%) 
5 FU/LV IV and/or XELODA 40 (11.0%) 
FOLFIRINOX 24 (6.6%) 
Other chemotherapy 3 (0.8%) 
Targeted therapy associated with first-line metastatic 
chemotherapy, n (%) 
N=372 
At least one targeted therapy prescribed 198 (53.2%) 
Targeted therapy, n (%) N=197 
Cetuximab 29 (14.7%) 
Bevacizumab 142 (72.1%) 
Panitumumab 23 (11.7%) 
Aflibercept 3 (1.5%) 
5-FU/LV IV: 5- 5-fluorouracil/leucovorin Intravenous; CRC: colorectal cancer; ECOG: 
Eastern Cooperative Oncology Group; FOLFOX: 5-fluorouracil, levofolinate, oxaliplatin; 
FOLFIRI: 5-fluorouracil, levofolinate, irinotecan; FOLFIRINOX: 5-fluorouracil, levofolinate, 
irinotecan, oxaliplatin; mCRC: metastatic colorectal cancer; N: number of patients with 
available data; SD: Standard Deviation; XELODA: capecitabine; XELOX: capecitabine, 
oxaliplatin 
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Table 2: Characteristics of the RAS/KRAS mutation testing requests 
 Total  
(N=375) 
RAS/KRAS mutation testing, n (%) N=375 
No mutation testing requested 37 (9.9%) 
At least one mutation test request 338 (90.1%) 
 RASa 292 (86.4%) 
 KRASb 31 (9.2%) 
 Genotyping mCRCc 9 (2.7%) 
 Missing data 6 (1.8%) 
Time between diagnosis of mCRC and RAS/KRAS mutation testing 
request, n (%) 
N=331 
>1 month prior to diagnosis of metastases 16 (4.8%) 
≤1 month before and ≤1 month after diagnosis of metastases 242 (73.1%) 
>1 month after diagnosis of metastases 73 (22.1%) 
Time between RAS/KRAS mutation testing request and initiation of 
first-line metastatic therapy, n (%) 
N=328 
Before the introduction of the first-line therapy 280 (85.4%) 
After the introduction of the first-line therapy 48 (14.6%) 
aRAS=RAS or KRAS+NRAS or KRAS+NRAS+BRAF 
bKRAS=KRAS or KRAS+BRAF or KRAS+BRAF+microsatellite instability (MSI) phenotype 
cGenotyping mCRC=BRAF+MSI phenotype or MSI phenotype or Genotyping or CRC 
biomarker 
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Table 3: Duration in days of the time between test request and receipt of the genotyping 
report for RAS/KRAS mutation testing  
 Duration in days from 
test request to 
dispatch of tumour 
material to platform 
(N=237) 
Duration in days from 
dispatch of tumour 
material to platform to 
receipt of the 
genotyping report 
(N=244) 
Duration in days from 
test request to receipt 
of the genotyping 
report 
 
(N=280) 
Mean ± SD 7.7 ± 11.3 19.5 ± 15.8 24.6 ± 17.2 
Median 4.0 15 20 
Q1-Q3 0.0-9.0 10.0-23.0 14.0-29.0 
Min; Max 0.0; 65.0 1.0; 112.0 1.0; 118.0 
Population: all patients, whatever the wording of the request, for whom there was a result for 
both KRAS and NRAS plus requests for RAS tests, for which there was at least one result for 
KRAS gene (N=304) 
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